Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs.
about
Mechanism of inhibition of the human immunodeficiency virus type 1 reverse transcriptase by d4TTP: an equivalent incorporation efficiency relative to the natural substrate dTTPPrevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analoguesAmino acid deletion at codon 67 and Thr-to-Gly change at codon 69 of human immunodeficiency virus type 1 reverse transcriptase confer novel drug resistance profilesIncreased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-Acid insert in the reverse transcriptase.Augmentation of human immunodeficiency virus type 1 subtype E (CRF01_AE) multiple-drug resistance by insertion of a foreign 11-amino-acid fragment into the reverse transcriptase.Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition.Genotypic testing for human immunodeficiency virus type 1 drug resistance.A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1Genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 variants with insertions or deletions in the reverse transcriptase (RT): multicenter study of patients treated with RT inhibitorsGenotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection.Nucleoside analog resistance caused by insertions in the fingers of human immunodeficiency virus type 1 reverse transcriptase involves ATP-mediated excision.Insertions in the reverse transcriptase increase both drug resistance and viral fitness in a human immunodeficiency virus type 1 isolate harboring the multi-nucleoside reverse transcriptase inhibitor resistance 69 insertion complex mutation.Frequency of mutations conferring resistance to nucleoside reverse transcriptase inhibitors in human immunodeficiency virus type 1-infected patients in Korea.Functional correlation between a novel amino acid insertion at codon 19 in the protease of human immunodeficiency virus type 1 and polymorphism in the p1/p6 Gag cleavage site in drug resistance and replication fitnessHIV resistance to antiretroviral drugs: mechanisms, genotypic and phenotypic resistance testing in clinical practice.Update on didanosine.Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms.Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitorsThe Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.Clinical significance of HIV reverse-transcriptase inhibitor-resistance mutations.Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations.A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184VPrevalence and conditions of selection of E44D/A and V118I human immunodeficiency virus type 1 reverse transcriptase mutations in clinical practiceVariants other than aspartic acid at codon 69 of the human immunodeficiency virus type 1 reverse transcriptase gene affect susceptibility to nuleoside analogs.Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus.Correlation of phenotypic zidovudine resistance with mutational patterns in the reverse transcriptase of human immunodeficiency virus type 1: interpretation of established mutations and characterization of new polymorphisms at codons 208, 211, and 2Effects of dipeptide insertions between codons 69 and 70 of human immunodeficiency virus type 1 reverse transcriptase on primer unblocking, deoxynucleoside triphosphate inhibition, and DNA chain elongation.Role of a dipeptide insertion between codons 69 and 70 of HIV-1 reverse transcriptase in the mechanism of AZT resistance.Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.Relative fitness and replication capacity of a multinucleoside analogue-resistant clinical human immunodeficiency virus type 1 isolate with a deletion of codon 69 in the reverse transcriptase coding region.Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel.Selection of human immunodeficiency virus type 1 variants with an insertion mutation in the p6(gag) and p6(pol) genes under highly active antiretroviral therapy.
P2860
Q28343830-CE473710-4A91-4111-8668-6798EEDAE9A1Q28344476-F5F55323-D193-420B-AEA0-280688D3622BQ28361269-551630FE-9A81-442C-8692-10E6BE4B907FQ33737755-0CEE861F-F8D3-473E-B82A-39D3C59D1463Q33841974-1D52C155-4AFF-4FA5-A89A-430AB894AB71Q33896402-10477109-66FD-455D-AAFF-3E1F35C1F474Q33906239-20B5584C-1312-4F8C-92F2-F4A4DCAF2460Q33979107-F778C5CD-5FE1-47DB-AF8D-290C0F248C38Q33982354-05EF0BD0-994E-41F1-8931-075CFDC05F57Q34084316-CCFE5794-F55E-458D-A2BE-4E4F228C9594Q34345605-A7C7EBAA-923E-4BD8-A7FC-F732C02CBCF3Q34348774-6D8EF92D-44E5-4BF5-8137-FD24B98CBF32Q34454702-09293EC5-7E8E-4968-82C7-F75265097A86Q34651403-5BB86589-2832-4B6D-B43F-BEC0FE3ABD17Q35014914-0CE51D47-9190-473D-935B-5CBA4736E238Q35207285-AC003782-58E3-419D-9612-2D8DFC7D3CC0Q36175788-08B66BE0-0B30-4E1B-9644-19DFD4BA83E0Q36498272-304A9565-78F0-4143-940A-96FD306E5148Q37018369-44F9076A-D0FE-4421-8EFE-C07B02AF2A59Q37859395-B6943AF5-193F-4096-8212-285D7770200BQ38344427-2FC4E458-5121-47BD-AFA7-F66A34934CF1Q39473036-CBC3F6D8-FF01-41E6-97C1-3DD7FEF44AB5Q39476701-EBA89A87-34A3-4AD5-AF49-E1A5A39B719FQ39477972-800659EB-777E-4BF9-B6E2-742EB7B32A63Q39601389-5C645BC7-2DCB-4CB8-80DD-2F6BC80E1FA2Q39730755-65658B66-E1F9-423E-AA93-9D368E51BC69Q39732544-138CD79B-4EAB-4D44-919A-D5C3D8FB0CE4Q40388003-007DD94D-C62C-4BDC-B233-EB1D97578C30Q42549637-4C07D6A6-E479-4E6E-AE74-0EFBE7E47E28Q42737965-42FA6127-94EC-47E5-8EB3-E728DEF92CA6Q45722783-7A31C6E5-ECA6-4EA5-AFCB-B5661B4B4D30Q45728754-C8C190C0-1715-4A1D-ABC3-DAE4B09C24F0
P2860
Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Insertion of two amino acids c ...... o multiple nucleoside analogs.
@en
Insertion of two amino acids c ...... o multiple nucleoside analogs.
@nl
type
label
Insertion of two amino acids c ...... o multiple nucleoside analogs.
@en
Insertion of two amino acids c ...... o multiple nucleoside analogs.
@nl
prefLabel
Insertion of two amino acids c ...... o multiple nucleoside analogs.
@en
Insertion of two amino acids c ...... o multiple nucleoside analogs.
@nl
P2093
P1433
P1476
Insertion of two amino acids c ...... o multiple nucleoside analogs.
@en
P2093
Goudsmit J
Hillebrand ME
Huismans R
Jurriaans S
Lukashov VV
de Jong JJ
ten Veen JH
P356
10.1097/00002030-199901140-00010
P407
P577
1999-01-01T00:00:00Z